Pembrolizumab for Early Triple-Negative Breast Cancer
Open accessThe DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Previous trials showed promising antitumor activity and an acceptable safety profile associated with pembrolizumab in patients with early triple-negative breast cancer. Whether the addition of pembrolizumab to neoadjuvant chemotherapy would significantly increase the percentage of patients with early triple-negative breast cancer who have a pathological complete response (defined as no invasive cancer in the breast and negative nodes) at definitive surgery is unclear. METHODS: In this phase 3 trial, we randomly assigned (in a 2:1 ratio) patients with previously untreated stage II or stage III triple-negative breast cancer to receive neoadjuvant therapy with four cycles of pembrolizumab (at a dose of 200 mg) every 3 weeks plus paclitaxel and carboplatin (784 patients; the pembrolizumab-chemotherapy group) or placebo every 3 weeks plus paclitaxel and carboplatin (390 patients; the placebo-chemotherapy group); the two groups then received an additional four cycles of pembrolizumab or placebo, and both groups received doxorubicin-cyclophosphamide or epirubicin-cyclophosphamide. After definitive surgery, the patients received adjuvant pembrolizumab or placebo every 3 weeks for up to nine cycles. The primary end points were a pathological complete response at the time of definitive surgery and event-free survival in the intention-to-treat population. RESULTS: At the first interim analysis, among the first 602 patients who underwent randomization, the percentage of patients with a pathological complete response was 64.8% (95% confidence interval [CI], 59.9 to 69.5) in the pembrolizumab-chemotherapy group and 51.2% (95% CI, 44.1 to 58.3) in the placebo-chemotherapy group (estimated treatment difference, 13.6 percentage points; 95% CI, 5.4 to 21.8; P<0.001). After a median follow-up of 15.5 months (range, 2.7 to 25.0), 58 of 784 patients (7.4%) in the pembrolizumab-chemotherapy group and 46 of 390 patients (11.8%) in the placebo-chemotherapy group had disease progression that precluded definitive surgery, had local or distant recurrence or a second primary tumor, or died from any cause (hazard ratio, 0.63; 95% CI, 0.43 to 0.93). Across all treatment phases, the incidence of treatment-related adverse events of grade 3 or higher was 78.0% in the pembrolizumab-chemotherapy group and 73.0% in the placebo-chemotherapy group, including death in 0.4% (3 patients) and 0.3% (1 patient), respectively. CONCLUSIONS: Among patients with early triple-negative breast cancer, the percentage with a pathological complete response was significantly higher among those who received pembrolizumab plus neoadjuvant chemotherapy than among those who received placebo plus neoadjuvant chemotherapy. (Funded by Merck Sharp & Dohme [a subsidiary of Merck]; KEYNOTE-522 ClinicalTrials.gov number, NCT03036488.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“improvement in overall survival has been reported in unresectable NSCLC patients and TNBC patients treated with anti PD-L1 antibody with chemotherapy”
From Hallmarks of response, resistance, and toxicity to immune checkpoint blockade (2021) · cites this paper as Schmid et al., 2020
In the citing paper
“Immune checkpoint blockade (ICB) directed against programmed death-1 (PD-1) or programmed death-ligand 1 (PD-L1) has shown promising results in TNBC4–6, but the overall response rate of ICB is less than 20%7.”
Citations
Cites
Toxicity and response criteria of the Eastern Cooperative Oncology Group
Oken, M. M., Creech, R. H., Tormey, D. C., Horton, J., Davis, T. E., McFadden, E. T., & Carbone, P. P. (1982) · AMERICAN JOURNAL OF CLINICAL ONCOLOGY · doi:10.1097/00000421-198212000-00014 · Cited by 11,647
Edge, S. B., & Compton, C. C. (2010) · Annals of Surgical Oncology · doi:10.1245/s10434-010-0985-4 · Cited by 9,029
Cortazar, P., Zhang, L., Untch, M., Mehta, K., Costantino, J. P., Wolmark, N., Bonnefoi, H., Cameron, D., Gianni, L., Valagussa, P., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(13)62422-8 · Cited by 4,742
Wolff, A. C., Hammond, M. E. H., Schwartz, J. N., Hagerty, K. L., Allred, D. C., Cote, R. J., Dowsett, M., Fitzgibbons, P. L., Hanna, W. M., Langer, A., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.2775 · Cited by 4,434
Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer
Schmid, P., Adams, S., Rugo, H. S., Schneeweiss, A., Barrios, C. H., Iwata, H., Diéras, V., Hegg, R., Im, S.-A., Shaw Wright, G., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1809615 · Cited by 4,350
Hammond, M. E. H., Hayes, D. F., Dowsett, M., Allred, D. C., Hagerty, K. L., Badve, S., Fitzgibbons, P. L., Francis, G., Goldstein, N. S., Hayes, M., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.6529 · Cited by 4,213
Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Aebi, S., Davidson, T., Gruber, G., & Castiglione, M. (2010) · Annals of Oncology · doi:10.1093/annonc/mdq159 · Cited by 2,842
Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Cardoso, F., Kyriakides, S., Ohno, S., Penault-Llorca, F., Poortmans, P., Rubio, I. T., Zackrisson, S., & Senkus, E. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz173 · Cited by 2,214
Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy
Masuda, N., Lee, S.-J., Ohtani, S., Im, Y.-H., Lee, E.-S., Yokota, I., Kuroi, K., Im, S.-A., Park, B.-W., Kim, S.-B., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1612645 · Cited by 1,888
Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study
Nanda, R., Chow, L. Q. M., Dees, E. C., Berger, R., Gupta, S., Geva, R., Pusztai, L., Pathiraja, K., Aktan, G., Cheng, J. D., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.64.8931 · Cited by 1,477
Self-citation
Research works printed but not linked: 1
- Qi C Huang M Haiderali A et al. Association between pathological complete responses and long-term survival outcomes among triple-negative breast cancer patients receiving neoadjuvant chemotherapy. Presented at the NCCN Annual Conference Orlando March 21–23 2019.
Cited by
Items 801–900 of 1,004
Song, Y., Li, N., Li, Q., Liang, X., Zhang, S., Fan, Q., Yin, X., Zhuang, Z., Liu, Y., Zhang, J., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001279 · Cited by 20
PD-1 protein and gene expression as prognostic factors in early breast cancer
Matikas, A., Zerdes, I., Lövrot, J., Sifakis, E. G., Richard, F., Sotiriou, C. P., Rassidakis, G. Z., Bergh, J. C. S., Valachis, A., & Foukakis, T. (2020) · ESMO Open · doi:10.1136/esmoopen-2020-001032 · Cited by 23
Industrializing engineered autologous T cells as medicines for solid tumours
Britten, C. M., Shalabi, A. M., & Hoos, A. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00175-8 · Cited by 21
Ohashi, T., Takase‐Minegishi, K., Maeda, A., Hamada, N., Yoshimi, R., Kirino, Y., Teranaka, H., Kunimoto, H., Hagihara, M., Matsumoto, K., et al. (2023) · Journal of Hematology · doi:10.14740/jh1090 · Cited by 20
Xiong, X., Wang, X., Liu, C., Shao, Z.-M., & Yu, K. (2024) · Biomarker Research · doi:10.1186/s40364-024-00654-1 · Cited by 23
Current Clinical Utility of Circulating Tumor DNA Testing in Breast Cancer: A Practical Approach
Xi, J., Ma, C. X., & O’Shaughnessy, J. (2024) · JCO Oncology Practice · doi:10.1200/op.24.00274 · Cited by 22
Trends and Disparities in the Use of Immunotherapy for Triple-Negative Breast Cancer in the US
Freeman, J. Q., Huo, D., Shubeck, S. P., Chen, N., Yarlagadda, S. R., Nanda, R., & Howard, F. M. (2025) · JAMA Network Open · doi:10.1001/jamanetworkopen.2024.60243 · Cited by 27
Combinational therapeutic strategies to overcome resistance to immune checkpoint inhibitors
Al-Saafeen, B. H., Ali, B. R., & Elkord, E. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1546717 · Cited by 27
Lin, Y., Yu, Y., Wang, Q., Huang, K., Guo, S., Zhang, J., He, Y., Yu, X., Zhang, J., Meng, F., et al. (2025) · npj Precision Oncology · doi:10.1038/s41698-025-01012-6 · Cited by 25
Ali, M. A., Aiman, W., Shah, S. S. H., Hussain, M., & Kashyap, R. (2020) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2020.103197 · Cited by 22
Finding the positive in triple-negative breast cancer
Carey, L. (2021) · Nature Cancer · doi:10.1038/s43018-021-00211-x · Cited by 21
Discordance of PD-L1 Expression at the Protein and RNA Levels in Early Breast Cancer
Zerdes, I., Karafousia, V., Mezheyeuski, A., Stogiannitsi, M., Kuiper, R., Moreno-Ruiz, P., Rassidakis, G. Z., Bergh, J. C. S., Hatschek, T., Foukakis, T., et al. (2021) · Cancers · doi:10.3390/cancers13184655 · Cited by 21
Lu, Y., Yeo, W., Yap, Y. S., Park, Y. H., Tamura, K., Li, H., & Cheng, R. (2021) · Targeted Oncology · doi:10.1007/s11523-021-00838-x · Cited by 24
Chun, B., Pucilowska, J., Chang, S., Kim, I., Nikitin, B. M., Koguchi, Y., Redmond, W. L., Bernard, B. M., Rajamanickam, V., Polaske, N. W., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-004033 · Cited by 25
Park, S., & Yi, G. (2022) · Cancers · doi:10.3390/cancers14040881 · Cited by 24
Stromal Characteristics and Impact on New Therapies for Metastatic Triple-Negative Breast Cancer
Fertal, S. A., Poterala, J. E., Ponik, S. M., & Wisinski, K. B. (2022) · Cancers · doi:10.3390/cancers14051238 · Cited by 21
Post-Neoadjuvant Treatment Strategies in Breast Cancer
Matuschek, C., Jazmati, D., Bölke, E., Tamaskovics, B. F., Corradini, S., Budach, W., Krug, D. A., Mohrmann, S., Ruckhäberle, E., Fehm, T. N., et al. (2022) · Cancers · doi:10.3390/cancers14051246 · Cited by 20
“Several trials tested the addition of immune checkpoint blockers in the neoadjuvant and adjuvant treatment of triple-negative breast cancer [2,3,11,12].”
BackgroundResultBarrios, C. H., Saji, S., Harbeck, N., Zhang, H., Jung, K. H., Patel, S., Patel, S., Duc, A. N., Liste-Hermoso, M., Chui, S. Y., et al. (2022) · npj Breast Cancer · doi:10.1038/s41523-022-00457-3 · Cited by 19
Emerging Targeted Therapies for Early Breast Cancer
Schlam, I. M., Tarantino, P., Morganti, S., Lynce, F. C., Trapani, D., Mayer, E. L., Garrido-Castro, A. C., Waks, A., & Tolaney, S. M. (2022) · Drugs · doi:10.1007/s40265-022-01781-5 · Cited by 19
“Notably, the benefit of pembrolizumab was demonstrated irrespective of programmed cell death ligand 1 (PD-L1) expression (PD-L1 positivity was defined as a combined positive score of ≥ 1 by the 22C3 assay) or nodal status [5, 12].”
BackgroundMethodResultInfluentialYazaki, S., Shimoi, T., Yoshida, M., Okuma, H. S., Arakaki, M., Saito, A., Kita, S., Yamamoto, K., Kojima, Y., Nishikawa, T., et al. (2022) · Breast Cancer Research and Treatment · doi:10.1007/s10549-022-06787-x · Cited by 25
Toss, A., Venturelli, M., Civallero, M., Piombino, C., Domati, F., Ficarra, G., Combi, F., Cabitza, E., Caggia, F., Barbieri, E., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.1016295 · Cited by 19
“According to our findings, the achievement of pCR should remain as the primary aim in these patients and should be pursued by optimizing NACT, for instance by the addition of platinum agents (10, 43) or pembrolizumab (44).”
MethodDowns‐Canner, S., & Mittendorf, E. A. (2023) · Annals of Surgical Oncology · doi:10.1245/s10434-023-13267-z · Cited by 21
“Adapted from Schmid et al.(5) Preoperative Immunotherapy Combined with Chemotherapy.”
MethodTissue- and liquid biopsy-based biomarkers for immunotherapy in breast cancer
Licata, L., Mariani, M., Rossari, F., Viale, G., Notini, G., Naldini, M. M., Bosi, C., Piras, M., Dugo, M., & Bianchini, G. (2023) · The Breast · doi:10.1016/j.breast.2023.03.014 · Cited by 19
Hope and Hype around Immunotherapy in Triple-Negative Breast Cancer
Jacobs, F., Agostinetto, E., Miggiano, C., Sanctis, R. D., Zambelli, A., & Santoro, A. (2023) · Cancers · doi:10.3390/cancers15112933 · Cited by 21
“While immunotherapy was continued after surgery in IMpassion031 and KEYNOTE-522 trials, GeparNuevo did not continue durvalumab postoperatively and still showed improvement EFS, suggesting that most of the benefit of ICI therapy is achieved in the neoadjuvant phase.”
BackgroundInfluentialAbuhadra, N. K., Sun, R., Yam, C., Rauch, G. M., Ding, Q., Lim, B., Thompson, A. M., Mittendorf, E. A., Adrada, B. E., Damodaran, S., et al. (2023) · Cancers · doi:10.3390/cancers15133275 · Cited by 21
“The patients in this study were enrolled and treated with anthracycline-based chemotherapy prior to the 2021 FDA approval of neoadjuvant and adjuvant pembrolizumab following results from the landmark trial KEYNOTE-522; however, the implications remain relevant [37].”
Adesoye, T., Everidge, S. A., Chen, J. H., Sun, S. X., Teshome, M. K., Valero, V., Woodward, W. A., & Lucci, A. (2023) · Annals of Surgical Oncology · doi:10.1245/s10434-023-13906-5 · Cited by 20
Analysis of Immune Resistance Mechanisms in TNBC: Dual Effects Inside and Outside the Tumor
Xu, J., Chen, G., Yu, S., Yao, S., Li, W., & Cheng, H. (2023) · Clinical Breast Cancer · doi:10.1016/j.clbc.2023.10.011 · Cited by 21
Zhong, W.-J., Lin, J., Wu, C., Wang, J., Chen, J., Zheng, H., & Ye, K. (2024) · Cancer Medicine · doi:10.1002/cam4.7006 · Cited by 18
“21,22 –28 Besides, in the randomized phase IIb DANTE study, the pCR rate was 25% in patients received neoadjuvant atezolizumab plus FLOT regimen, 24% in the neoadjuvant FLOT group, whereas the MPR rates between these two groups were 49% and 44%, respectively.”
BackgroundBaskin, A. S., Huppert, L. A., Kelil, T., Singer, L., & Mukhtar, R. A. (2024) · Surgical Oncology Insight · doi:10.1016/j.soi.2024.100059 · Cited by 25
Mohamed, R. M. M., Panthi, B., Adrada, B. E., Böge, M., Candelaria, R. P., Chen, H., Guirguis, M. S., Hunt, K. K., Huo, L., Hwang, K., et al. (2024) · Scientific Reports · doi:10.1038/s41598-024-66220-9 · Cited by 24
Recent advances in neoadjuvant therapy for breast cancer
Potter, D. A., Herrera-Ponzanelli, C., Ugarte, D. H., Castillo, R., Hernández-Cruz, I. A., Arrieta, V. A., Franklin, M. J., & Yee, D. (2021) · Faculty Reviews · doi:10.12703/r/10-2 · Cited by 21
Tumor-Infiltrating Lymphocyctes in Triple-Negative Breast Cancer: Update for 2020
Brown, L. C., Salgado, R., Luen, S. J., Savas, P. S., & Loi, S. (2021) · The Cancer Journal · doi:10.1097/ppo.0000000000000501 · Cited by 22
Quintana, Á., Peg, V., Prat, A., Moliné, T., Villacampa, G. J., Paré, L., Galván, P., Dienstmann, R., Schmid, P., Curigliano, G., et al. (2021) · European Journal of Cancer · doi:10.1016/j.ejca.2021.01.037 · Cited by 20
Molecular Targets and Promising Therapeutics of Triple-Negative Breast Cancer
Ryu, W., & Sohn, J. (2021) · Pharmaceuticals · doi:10.3390/ph14101008 · Cited by 23
Advances in the study of tertiary lymphoid structures in the immunotherapy of breast cancer
Li, X., Han, X., Du, Z., Cao, Q., & Liu, X. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1382701 · Cited by 19
Caspase-1-dependent spatiality in triple-negative breast cancer and response to immunotherapy
Zheng, W., Marini, W., Murakami, K., Sotov, V., Butler, M. O., Gorrini, C., Ohashi, P. S., & Reedijk, M. (2024) · Nature Communications · doi:10.1038/s41467-024-52553-6 · Cited by 19
Cai, Y., Liu, C., Zhang, Y., Liu, Y., Chen, L., Xiong, X., Shao, Z., & Yu, K. (2024) · Journal of Clinical Investigation · doi:10.1172/jci183656 · Cited by 25
“Currently, certain progress has been made for immunotherapy in treating TNBC (22, 23) and the FDA has approved pembrolizumab for this disease.”
InfluentialImmunotherapy in Triple-Negative Breast Cancer
Tiberi, E., Parisi, A., Pistelli, M., Savini, A., Galassi, F., Reschini, C., Quintavalle, D., Napoleoni, R., Ferrari, C., & Berardi, R. (2025) · Oncology and Therapy · doi:10.1007/s40487-025-00346-2 · Cited by 24
“Moreover, at a median follow-up of 39 months, the addition of pembrolizumab to NACT improved the 3-year EFS from 76.8 to 84.5% [hazard ratio (HR) 0.63, p = 0.0003] [12].”
InfluentialDauccia, C., Agostinetto, E., Arecco, L., Lobo-Martins, S., Gitto, M., Lyon, A. R., López‐Fernández, T., Dent, S. F., Casalino, G., Agarwala, V., et al. (2025) · ESMO Open · doi:10.1016/j.esmoop.2025.105128 · Cited by 21
Gupta, S., Nair, N. S., Hawaldar, R. W., Joshi, S. P., Gulia, S., Shet, T. M., Sarin, R., Parmar, V. V., Desai, S. B., Ghosh, J., et al. (2025) · Journal of Clinical Oncology · doi:10.1200/jco-25-01023 · Cited by 46
Marinelli, D., Mazzotta, M., Pizzuti, L., Krasniqi, E., Gamucci, T., Natoli, C., Grassadonia, A., Tinari, N., Tomao, F., Sperduti, I., et al. (2020) · Cancers · doi:10.3390/cancers12092497 · Cited by 21
Feng, W., He, Y., Xu, J., Zhang, H., Si, Y., Xu, J., & Li, S. (2021) · Anti-Cancer Drugs · doi:10.1097/cad.0000000000001196 · Cited by 21
Chang, E., Apolo, A. B., Bangs, R., Chisolm, S., Duddalwar, V. A., Efstathiou, J. A., Goldberg, K. B., Hansel, D. E., Kamat, A. M., Kluetz, P. G., et al. (2021) · Nature Reviews Urology · doi:10.1038/s41585-021-00505-w · Cited by 20
Rodríguez‐Bautista, R., Caro-Sánchez, C. H. S., Cabrera‐Galeana, P., Alanis-Funes, G. J., Gutiérrez-Millán, E., Ávila‐Ríos, S., Matías‐Florentino, M., Reyes‐Terán, G., Díaz‐Chávez, J., Villarreal-Garza, C. M., et al. (2021) · Cancers · doi:10.3390/cancers13246256 · Cited by 22
Shafi, S., Aung, T. N., Xirou, V., Gavrielatou, N., Vathiotis, I. A., Fernandez, A. I., Moutafi, M. K., Yaghoobi, V., Herbst, R. S., Liu, L. N., et al. (2022) · Laboratory Investigation · doi:10.1038/s41374-022-00796-6 · Cited by 23
Contemporary breast cancer treatment-associated thrombosis
Kirwan, C., & Blower, E. (2022) · Thrombosis Research · doi:10.1016/j.thromres.2021.12.025 · Cited by 18
Santa-Maria, C. A., O’Donnell, M., Nunes, R., Wright, J. L., & Stearns, V. (2022) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2022.7025 · Cited by 19
Yang, C., Zhang, J., Zhang, Y., Ji, F., Chen, Y., Zhu, T., Zhang, L., Gao, H., Yang, M., Li, J., et al. (2022) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359221118053 · Cited by 20
Standardizing Pathologic Evaluation of Breast Carcinoma After Neoadjuvant Chemotherapy
Sahoo, S., Krings, G., Chen, Y., Carter, J. M., Chen, B., Guo, H., Hibshoosh, H. H., Reisenbichler, E., Fan, F., Wei, S., et al. (2022) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2022-0021-ep · Cited by 18
Abdel‐Razeq, H., Khalil, H., Assi, H. I., & Dargham, T. B. (2022) · Current Oncology · doi:10.3390/curroncol29080458 · Cited by 19
“Pembrolizumab + standard chemotherapy [77] 64.”
Zhu, Y., Tzoras, E., Matikas, A., Bergh, J. C. S., Valachis, A., Zerdes, I., & Foukakis, T. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.999843 · Cited by 20
“The response to PD(L)-1 inhibition seems independent of PD-L1 status in the neoadjuvant setting (66), while in the GeparNuevo trial, TILs at baseline were predictive for pCR in TNBC patients receiving neoadjuvant chemotherapy with or without durvalumab, with no significant interaction between TILs and treatment arms (…”
ResultWang, X., Ling, X., Wang, C., Zhang, J., Yang, Y., Jiang, H., Xin, Y., Zhang, L., Liang, H., Fang, C., et al. (2022) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-022-03354-7 · Cited by 18
Deng, H., Wang, L., Wang, N., Zhang, K., Zhao, Y., Qiu, P., Qi, X., Zhang, D., Xu, F., & Liu, J. (2023) · BMC Cancer · doi:10.1186/s12885-023-10515-z · Cited by 19
“Neoadjuvant therapy for patients with TNBC has been revolutionized with the introduction of new agents, including anti-PD-1/L1 antibodies [12].”
BackgroundResultInfluentialInsertion of (Bioactive) Equatorial Ligands into Platinum(IV) Complexes
Kastner, A., Schueffl, H. H., Yassemipour, P. A., Keppler, B. K., Heffeter, P., & Kowol, C. R. (2023) · Angewandte Chemie International Edition · doi:10.1002/anie.202311468 · Cited by 17
Liquid biopsy biomarkers to guide immunotherapy in breast cancer
Yang, J., Qiu, L., Wang, X., Chen, X., Cao, P., Yang, Z., & Wen, Q. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1303491 · Cited by 20
Alamoodi, M. (2023) · European Journal of Breast Health · doi:10.4274/ejbh.galenos.2023.2023-11-2 · Cited by 18
“In the pivotal KEYNOTE-522 clinical trial, pCR rates of 65% and 69% were reported for chemotherapy plus pembrolizumab in the overall and PD-L1-positive subgroups, respectively (45).”
BackgroundThe role of spine stereotactic radiosurgery for patients with breast cancer metastases
Taori, S., Adida, S., Tang, A., Rajan, A., Sefcik, R. K., Burton, S. A., Flíckinger, J. C., Zinn, P. O., & Gerszten, P. C. (2024) · Journal of Neuro-Oncology · doi:10.1007/s11060-024-04599-1 · Cited by 18
“…mTOR inhibitors, PI3K inhibitors, PARP inhibitors), and immunotherapies (i.e., trastuzumab, per-tuzumab, pembrolizumab) have all demonstrated some level of survival or progression-free improvement in select clinical trials for metastatic breast cancer spread of varying histology’s [41–45].”
InfluentialMartín, M., Yoder, R., Salgado, R., del Monte-Millán, M., Álvarez, E. L., Echavarría, I., Staley, J. M., O’Dea, A. P., Nye, L. E., Stecklein, S. R., et al. (2024) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-24-0106 · Cited by 23
Liu, Z., Li, J., Zhao, F., Ren, D., Li, Z., Chen, Y., Huang, S., Liu, Z., Zhao, Y., Wang, M., et al. (2024) · BMC Cancer · doi:10.1186/s12885-024-12222-9 · Cited by 22
“Immune checkpoint inhibitor (ICI) therapy is directed against the interaction between the pro - grammed death protein 1 (PD-1) and programmed death ligand 1 (PD-L1) [20, 21].”
BackgroundThe roles of PD-L1 in the various stages of tumor metastasis
He, Y., Zhu, M. Q., Lai, X., Zhang, H., & Jiang, W. (2024) · Cancer and Metastasis Reviews · doi:10.1007/s10555-024-10189-4 · Cited by 22
“What’s more, administrations of PD-(L)1 blockades Yinjun He, Ming Zhu and Xuan Lai contributed equally to this work. in neoadjuvant and adjuvant settings also reduce the risk of distant metastasis [18–21], emphasizing the involvement of PD-L1 during the metastasis process.”
Shen, G., Liu, Z., Wang, M., Zhao, Y., Liu, X., Hou, Y., Ma, W., Han, J., Zhou, X., Ren, D., et al. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02137-7 · Cited by 25
Gyawali, B., D’Andrea, E., Franklin, J. M., & Kesselheim, A. S. (2021) · EClinicalMedicine · doi:10.1016/j.eclinm.2021.100730 · Cited by 19
ITM2A as a Tumor Suppressor and Its Correlation With PD-L1 in Breast Cancer
Zhang, R., Xu, T., Xia, Y., Wang, Z., Li, X., & Chen, W. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2020.581733 · Cited by 24
Jenkins, S. B., Wesolowski, R., & Gatti-Mays, M. E. (2021) · Current Oncology Reports · doi:10.1007/s11912-021-01040-y · Cited by 18
Recent updates in systemic therapy of breast cancer: A brief narrative review
Arora, S., & Gogia, A. (2021) · Cancer Research Statistics and Treatment · doi:10.4103/crst.crst_335_20 · Cited by 19
Bockstal, M. V., Cooks, M., Nederlof, I., Brinkhuis, M., Dutman, A. C., Koopmans, M., Kooreman, L. F. S., van der Vegt, B., Verhoog, L. C., Vreuls, C., et al. (2021) · Cancers · doi:10.3390/cancers13194910 · Cited by 21
Liu, C., Li, Y., Xing, X., Zhuang, J., Wang, J., Wang, C., Zhang, L., Liu, L., Feng, F., Li, H., et al. (2022) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2022.04.034 · Cited by 20
“17 However, this bene fi t was observed regardless of PD-L1 status.”
Walsh, E. M., Gucalp, A., Patil, S. N., Edelweiss, M., Ross, D. S., Razavi, P., Modi, S., Iyengar, N. M., Sanford, R. A., Troso-Sandoval, T. A., et al. (2022) · Breast Cancer Research and Treatment · doi:10.1007/s10549-022-06669-2 · Cited by 18
“This 3-year DFS rate is also comparable to the 3-year event-free survival (EFS) of 77% in the control arm of the recently reported KEYNOTE-522 study, where the anti-PD-1 antibody pembrolizumab was added to a regimen of carboplatin/ paclitaxel followed by anthracycline/cyclophosphamide in early-stage TNBC [32, 33].”
ResultAguiar-Ibáñez, R., Mbous, Y. P. V., Sharma, S., & Chawla, E. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1546447 · Cited by 17
Preoperative Strategies for Locally Advanced Colon Cancer
Nair, K. G., Kamath, S. D., Chowattukunnel, N., & Krishnamurthi, S. (2024) · Current Treatment Options in Oncology · doi:10.1007/s11864-024-01184-6 · Cited by 19
Khoury, K. E., Meisel, J. L., Yau, C. S. F., Rugo, H. S., Nanda, R., Davidian, M., Tsiatis, B., Chien, A. J., Wallace, A. M., Arora, M., et al. (2024) · Nature Medicine · doi:10.1038/s41591-024-03266-2 · Cited by 27
“Over 12 years, 23 drugs and drug combinations were evaluated, with some—such as pembrolizumab—going on to phase 3 trials and changing the standard of care worldwide for women with some of the highest-risk subtypes of breast cancer 1,2 .”
Inhibition of Notch enhances efficacy of immune checkpoint blockade in triple-negative breast cancer
Shen, Q., Murakami, K., Sotov, V., Butler, M. O., Ohashi, P. S., & Reedijk, M. (2024) · Science Advances · doi:10.1126/sciadv.ado8275 · Cited by 20
“This preclinical work provides the rationale for future clinical trials to test whether IL-1 β− or CCL2-targeted therapy improves outcome in patients with stage 2/3 TNBC receiving standard- of-care ( 34 ) pembrolizumab ICB/taxane-platinum/ anthracycline-based chemotherapy.”
BackgroundInfluentialLopes, N., Correia, V. G., Palma, A. S., & Brito, C. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22041972 · Cited by 20
Stovgaard, E. S., Asleh, K., Riaz, N., Leung, S. C. Y., Gao, D., Nielsen, L. B., Lænkholm, A., Balslev, E., Jensen, M., Nielsen, D. L., et al. (2021) · OncoImmunology · doi:10.1080/2162402x.2021.1924492 · Cited by 17
Multi-Gene Testing Overview with a Clinical Perspective in Metastatic Triple-Negative Breast Cancer
Dameri, M., Ferrando, L., Cirmena, G., Vernieri, C., Pruneri, G., Ballestrero, A., & Zoppoli, G. M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22137154 · Cited by 19
Immunotherapy in Breast Cancer and the Potential Role of Liquid Biopsy
Magbanua, M. J. M., Gümüşay, Ö., Kurzrock, R., Veer, L. V. ‘., & Rugo, H. S. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.802579 · Cited by 20
“KEYNOTE-522 (20, 64) TNBC III Pembro+Carbo+Pac PBO+Carbo+Pac NA NA NA 64.”
BackgroundInfluentialde Boniface, J., Altena, R., Ringborg, C. H., Bolam, K. A., & Wengström, Y. (2022) · PLoS ONE · doi:10.1371/journal.pone.0274804 · Cited by 17
Prognostic Impact of LAG-3 mRNA Expression in Early Breast Cancer
Heimes, A.-S., Almstedt, K., Krajnak, S., Runkel, A., Droste, A., Schwab, R. M., Stewen, K., Lebrecht, A., Battista, M. J., Brenner, W., et al. (2022) · Biomedicines · doi:10.3390/biomedicines10102656 · Cited by 19
“In early triple-negative breast cancer, recent phase III data have also demonstrated the efficacy of pembrolizumab in combination with neoadjuvant chemotherapy [7,26].”
BackgroundEnnis, C. S., Llévenes, P., Qiu, Y., Dries, R., & Denis, G. V. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.1044670 · Cited by 21
Facts and Hopes in Immunotherapy for Early-Stage Triple-Negative Breast Cancer
Nederlof, I., Voorwerk, L., & Kok, M. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-0701 · Cited by 18
“6% in the placebo arm comparedwith 63% in the pembrolizumab arm (15) at the second interim analysis with 1,174 patients randomized.”
BackgroundHigh PD-L2 Predicts Early Recurrence of ER-Positive Breast Cancer
Chervoneva, I., Peck, A. R., Sun, Y., Yi, M., Udhane, S. S., Langenheim, J. F., Girondo, M. A., Jorns, J. M., Chaudhary, L. N., Kamaraju, S., et al. (2023) · JCO Precision Oncology · doi:10.1200/po.21.00498 · Cited by 18
“The KEYNOTE-522 trial resulted in the recent approval of pembrolizumab in the neoadjuvant chemotherapy setting in TNBC regardless of PD-L1 status.(24) Collectively, these observations suggest that biomarkers are needed to stratify patients for these therapies, especially for ER+ breast cancer with lower response rates.”
BackgroundMei, T., Wang, T., Deng, Q., & Gong, Y. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1062679 · Cited by 19
Yam, C., Mittendorf, E. A., Garber, H. R., Sun, R., Damodaran, S., Murthy, R. K., Ramirez, D. L., Karuturi, M. S., Layman, R. M., Ibrahim, N. K., et al. (2023) · Breast Cancer Research and Treatment · doi:10.1007/s10549-023-06929-9 · Cited by 20
Zhou, Y., Zhou, J., Hao, X., Shi, H., Li, X., Wang, A., Hu, Z., Yang, Y., Jiang, Z., & Wang, T. (2023) · Breast Cancer Research and Treatment · doi:10.1007/s10549-023-06972-6 · Cited by 19
Hao, W., Zhang, J., Wang, Y., Fang, B., Jin, S., Yuan, J., & Cai, W. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1175809 · Cited by 19
Zattarin, E., Taglialatela, I., Lobefaro, R., Leporati, R., Fucà, G., Ligorio, F., Sposetti, C., Provenzano, L., Azzollini, J., Vingiani, A., et al. (2023) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2023.104109 · Cited by 23
Roy, A. M., Patel, A., Catalfamo, K., Attwood, K. M., Khoury, T., Yao, S., & Gandhi, S. (2023) · JAMA Network Open · doi:10.1001/jamanetworkopen.2023.44517 · Cited by 17
Mitochondrial dynamics as a novel treatment strategy for triple‐negative breast cancer
Wang, Y., Harada‐Shoji, N., Kitamura, N., Yamazaki, Y., Ebata, A., Amari, M., Watanabe, M., Miyashita, M., Tada, H., Abe, T., et al. (2024) · Cancer Medicine · doi:10.1002/cam4.6987 · Cited by 21
Cao, C., Lu, Y. C., Pan, X., Lin, Y., Fan, S., Niu, J., Lin, S., Tan, H., Wang, Y., Cui, S., et al. (2024) · Advanced Healthcare Materials · doi:10.1002/adhm.202304249 · Cited by 20
PP2A as a potential therapeutic target for breast cancer: Current insights and future perspectives
Qi, Y., Li, L., Wei, Y., & Ma, F. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.116398 · Cited by 17
Ali, K., Nabeel, M., Mohsin, F., Iqtedar, M., Islam, M. F., Rasool, M. F., Hashmi, F. K., Hussain, S. A., & Saeed, H. (2024) · Medical Oncology · doi:10.1007/s12032-024-02347-z · Cited by 24
Myers, S. P., Sevilimedu, V., Jones, V. M., Abuhadra, N. K., Montagna, G., Plitas, G., Morrow, M., & Downs‐Canner, S. (2024) · Annals of Surgical Oncology · doi:10.1245/s10434-024-15359-w · Cited by 22
“2 In some patients, immune checkpoint inhibitors can be reinitiated concurrently with steroid taper after symptoms of adverse events have resolved.”
Bullock, K. K., & Richmond, A. J. (2024) · Cancers · doi:10.3390/cancers16122189 · Cited by 22
“Tumors can broadly be described as either “hot” or “cold” tumors, meaning the presence or absence of anti-tumor immune cells, respectively.”
BackgroundSynergizing Immunotherapy and Antibody–Drug Conjugates: New Horizons in Breast Cancer Therapy
Pinto, A., Guarini, C., Giampaglia, M., Sanna, V., Melaccio, A., Lanotte, L., Santoro, A. N., Pini, F., Cusmai, A., Giuliani, F., et al. (2024) · Pharmaceutics · doi:10.3390/pharmaceutics16091146 · Cited by 18
“The KEYNOTE-522 [15] trial investigated the efficacy of pembrolizumab, an anti-PD-1 antibody, in combination with chemotherapy as a neoadjuvant treatment for early-stage TNBC.”
BackgroundCorti, C., Kurt, B. B., Koca, B., Rahman, T., Conforti, F., Pala, L., Bianchini, G., Criscitiello, C., Curigliano, G., Garrido-Castro, A. C., et al. (2024) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2024.102852 · Cited by 22
Landmark trials in the medical oncology management of early stage breast cancer
Hensing, W. L., Santa-Maria, C. A., Peterson, L. L., & Sheng, J. Y.-S. (2020) · Seminars in Oncology · doi:10.1053/j.seminoncol.2020.08.001 · Cited by 17
Clinical Data on Immunotherapy in Breast Cancer
Radosa, J. C., Stotz, L., Müller, C., Kaya, A. C., Solomayer, E., & Radosa, M. P. (2020) · Breast Care · doi:10.1159/000511788 · Cited by 20
Schreiber, A., Kagihara, J. A., Weiss, J. A., Nicklawsky, A., Gao, D., Borges, V. F., Kabos, P., & Diamond, J. R. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.640690 · Cited by 16
Ghosh, J., Chatterjee, M., Ganguly, S., Datta, A., Biswas, B., Mukherjee, G., Agarwal, S. K., Ahmed, R., Chatterjee, S., & Dabkara, D. (2021) · ecancermedicalscience · doi:10.3332/ecancer.2021.1217 · Cited by 16
Haiderali, A., Rhodes, W., Gautam, S., Huang, M., Sieluk, J., Skinner, K. E., & Schwartzberg, L. S. (2021) · Future Oncology · doi:10.2217/fon-2021-0530 · Cited by 17
Metadata
- Authors
- Schmid, P., Cortes, J., Pusztai, L., McArthur, H., Kümmel, S., Bergh, J., Denkert, C., Park, Y. H., Hui, R., Harbeck, N., Takahashi, M., Foukakis, T., Fasching, P. A., Cardoso, F., Untch, M., Jia, L., Karantza, V., Zhao, J., Aktan, G., Dent, R., & O’Shaughnessy, J.
- Affiliations
- Queen Mary University of London (GB)
- IOB Institute of Oncology, Quiron Group;Vall d’Hebron Institute of Oncology (VHIO), Madrid & Barcelona, Spain
- Yale Cancer Center (US)
- Cedars-Sinai Medical Center (US)
- Kliniken Essen-Mitte (DE)
- Karolinska University Hospital (SE)
- Philipps University of Marburg (DE)
- Samsung Medical Center (KR)
- The University of Sydney (AU)
- Ludwig-Maximilians-Universität München (DE)
- Sapporo National Hospital (JP)
- Universitätsklinikum Erlangen (DE)
- Breast Unit, Champalimaud Clinical Center/Champalimaud Foundation, Lisbon, Portugal
- Helios Hospital Berlin-Buch (DE)
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- National University of Singapore (SG)
- Baylor University Medical Center (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2020-02-27
- Volume
- 382
- Issue
- 9
- Pages
- 810-821
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W3006930853
- Cited by
- 3,270
- References
- 31
- Citations by year
- 2026: 580 · 2025: 576 · 2024: 552 · 2023: 500 · 2022: 514 · 2021: 391 · 2020: 152
- FWCI
- 133.41
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA (N/A)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › MRI in cancer diagnosis
- Keywords
- pembrolizumab, triple-negative breast cancer, early breast cancer, neoadjuvant immunotherapy, neoadjuvant chemotherapy, paclitaxel, carboplatin, pathological complete response, event-free survival, immune checkpoint inhibitors, doxorubicin-cyclophosphamide, epirubicin-cyclophosphamide
- MeSH terms
- Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Cyclophosphamide, Doxorubicin, Female, Humans, Middle Aged, Neoplasm Staging, Epirubicin, Carboplatin, Paclitaxel, Neoadjuvant Therapy, Kaplan-Meier Estimate, Intention to Treat Analysis, Antibodies, Monoclonal, Humanized, Triple Negative Breast Neoplasms
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.